SLFN5 and cancer: As a transcriptional repressor, SLFN5 prevents epithelial-mesenchymal transition (EMT) in breast cancer and targets the ZEB1 promoter to abrogate ZEB1 transcription and the downstream PTEN/AKT/cyclin D1 signaling cascade, ultimately prompting cancer cell death37,82.